TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03526380

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral: the OPT-IN Intervention
Description: A private one-on-one brief motivational interviewing intervention administered by non-research staff at community organizations. This will take up to 30 minutes to complete. The goal of the intervention is to improve opioid safety and reduce related overdoses among those who has a history of misusing opioids (prescription and illicit). The session will use techniques to change behavior in a respectful, non-confrontational, and non-judgmental manner. This intervention will also seek to empower participants by providing content on bystander response as well as peer outreach, which emphasizes ways to discuss overdose risk with others at risk for overdose.
Study: NCT03355482

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylprednisolone
Description: 160mg IM at baseline

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Placebos
Description: IM saline injection at baseline
Study: NCT03720314

Intervention type: OTHER
Intervention: NA observational study
Description: observational study

Intervention type: OTHER
Intervention: NA observational study
Description: observational study
Study: NCT00472693

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab, Abraxane
Description: Bevacizumab, 10 mg/m2 IV days 1 and 15; ABI-007, 100 mg/m2 IV days 1, 8, 15 of each 28 day cycle. Continue treatment until disease progression, patient withdrawal or unacceptable toxicities.
Study: NCT02075801

Intervention type: OTHER
Intervention: Sealing of amalgam margin defects
Description: Comparison between sealing of amalgam margins defects, replacement and non treated groups.

Intervention type: OTHER
Intervention: Sealing of amalgam margin defects
Description: A.Sealing of amalgam margin defects: were acid etched with 35% phosphoric acid for 15 seconds. A resin-based sealant (Clinpro Sealant, 3MESPE) was applied over the defective area. The sealant was polymerized with a photocuring unit (Curing Light 2500, 3M ESPE) for 40 seconds. Rubber dam isolation was used for this procedure. All treatments were applied by the same clinician.~B.Replacement Group: The clinician totally removed and replaces the defective restoration with a new amalgam (Tytin, Kerr Corporation, Orange, CA, USA). Rubber dam isolation was used for this procedure. All treatments were applied by the same clinician.~C.Control Group: The defective restorations did not receive any treatment.
Study: NCT03209401

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niraparib
Description: an oral PARP inhibitor
Study: NCT01223443

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Paclitaxel eluting stent
Description: Patients are randomized to either stenting the moderate SVG lesion with the paclitaxel stent or standard medical treatment
Study: NCT01579812

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Patients receiving primary surgical debulking followed by adjuvant chemotherapy will initiate metformin prior to primary surgery. Following surgery patients will be initiated on metformin prior to the initiation of chemotherapy.~Patients treated with neoadjuvant chemotherapy will be initiated on metformin prior to the initiation of chemotherapy. Following surgery patients will be initiated on metformin prior to the re-initiation of chemotherapy.
Study: NCT02612831

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Early bariatric surgery
Study: NCT03209401

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: a platinum-based injection
Study: NCT01370317

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for MK-1029
Description: Five (5) X 100 mg capsules, orally, once daily for 28 days
Study: NCT05258474

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: controlled-ileocolonic-release nicotinamide (SAD/MAD/MD)
Description: single- and multiple-ascending dose (SAD/MAD) or multiple dose (MD)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: controlled-ileocolonic-release nicotinamide (SAD/MAD/MD)
Description: single- and multiple-ascending dose (SAD/MAD) or multiple dose (MD)
Study: NCT02692625

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: (L. reuteri Prodentis®).
Description: The Test group is instructed to consume Probiotic lozenges for two months. The counts of salivary mutans streptococci and lactobacilli were evaluated using the CRT test at baseline, one-month, and two- months, from the beginning of the trial for every participating child.
Study: NCT02612831

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Delayed bariatric surgery
Study: NCT01138176

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cooling
Description: Reduction of rectal temperature to 33.5 C

Intervention type: PROCEDURE
Group type: NO_INTERVENTION
Intervention: Cooling
Description: Reduction of rectal temperature to 33.5 C
Study: NCT03452449

Intervention type: PROCEDURE
Intervention: planned lumbar spine surgery
Description: planned lumbar spine surgery including decompression, discectomy, foraminotomy, laminectomy
Study: NCT01970904

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alisporivir
Description: Alisporivir 100 mg or 200 mg soft gel capsules (SGC) in blister packs for oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alisporivir
Description: Alisporivir 100 mg or 200 mg soft gel capsules (SGC) in blister packs for oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alisporivir
Description: Alisporivir 100 mg or 200 mg soft gel capsules (SGC) in blister packs for oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: Ribavirin tablets of various strengths for oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: Ribavirin tablets of various strengths for oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: Ribavirin tablets of various strengths for oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peg-IFNα2a
Description: Peg-IFNα2a solution for subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peg-IFNα2a
Description: Peg-IFNα2a solution for subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peg-IFNα2a
Description: Peg-IFNα2a solution for subcutaneous injection
Study: NCT03381534

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: stenting with EPD
Description: participants will be randomly assigned to control group or experimental group,patients in control group will be undergone stenting of vertebral artery origin without embolic protection device,patient in experimental group will be undergone stenting of vertebral artery origin with embolic protection device

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: stent assisted angioplasty
Description: participants will be randomly assigned to control group or experimental group,patients in control group will be undergone stenting of vertebral artery origin without embolic protection device,patient in experimental group will be undergone stenting of vertebral artery origin with embolic protection device
Study: NCT02692625

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo lozenges
Description: The control group is instructed to consume placebo lozenges for two months. The counts of salivary mutans streptococci and lactobacilli were evaluated using the CRT test at baseline, one-month, and two- months, from the beginning of the trial for every
Study: NCT03691740

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Ocular light
Description: A light mask to which small light emitting diode(LED) lights emitting a blue or red color light will be used to deliver ocular light

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ocular light
Description: A light mask to which small light emitting diode(LED) lights emitting a blue or red color light will be used to deliver ocular light
Study: NCT04187287

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Radial Extracorporeal Shock Wave Therapy
Description: Radial Extracorporeal Shock Wave Therapy will given for 3 weeks, 1 days in a week. moreover 10-12 minutes cold pack will apply for every session

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Deep Friction Massage
Description: Deep Friction Massage will given for 3 weeks, 3 days in a week. Massage duration will be 10-15 min. for each session. Moreover 10-12 minutes cold pack will apply for every session. Also Mill's manipulation technique will applied once a week during 3 weeks.
Study: NCT00493857

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nimotuzumab Humanized Monoclonal Antibody
Description: Nimotuzumab 400mg every week

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nimotuzumab
Description: Nimotuzumab 400mg every 2 weeks
Study: NCT00686634

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitagliptin
Description: Sitagliptin 100 mg by mouth once daily
Study: NCT04095637

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Medial knee arthroplasty
Description: Surgical intervention where the medial portion of the knee is replaced by an artificial metal and polyethylene implant

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Medial knee arthroplasty
Description: Surgical intervention where the medial portion of the knee is replaced by an artificial metal and polyethylene implant
Study: NCT00906438

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 2006-RD-05
Description: 300 mg daily, once a day for 28 consecutive days

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Capsule similar in shape, weight and color from active, once a day for 28 consecutive days
Study: NCT00734955

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 49-channel optical spectrometer

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 49-channel optical spectrometer

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 49-channel optical spectrometer
Study: NCT01214057

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol and Remifentanyl
Description: Anesthesia will be induced with lidocaine 0.5 mg kg, propofol infusion at 250 mcg/kg/min (to reduce visual bias of propofol infusion) and total volume infused will be adjusted for an induction dose of 2-3 mg/kg before bolus of muscle relaxant, rocuronium 0.5 mg kg in both SR and PR groups. Remifentanil infusion will be started at a rate of 0.4 mcg/kg/min 1-2 minutes before the propofol infusion and a 100 ml 0.9% normal saline bag will be used to blind surgeons in the sevoflurane group. The target mean arterial blood pressure (MAP) will be maintained at 70-80 mm Hg by adjusting the propofol concentration within their range (100-150 mg ml for propofol) according to the anaesthesiologist's judgement and by surgeon request. If this failed, the remifentanil rate will be adjusted by 0.05 mg kg min.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sevoflurane and Remifentanyl
Description: Sevoflurane 1-3% will be administered in group SR, and the infusion of propofol will be stopped. After intubation remifentanil infusion will be changed to 0.2 mcg/kg/min. The target mean arterial blood pressure (MAP) will be maintained at 70-80 mm Hg by adjusting the sevoflurane concentration within their range (between 1-3 vol% for sevoflurane) according to the anaesthesiologist's judgement and by surgeon request.If this failed, the remifentanil rate will be adjusted by 0.05 mg kg min.In order to limit the amount of fluids remifentanil wil be diluted at a concentration of 4 mg in 100 ml.
Study: NCT00880464

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous, Lethally Irradiated Breast Cancer Cells
Description: Vaccination with autologous tumor cells engineered by adenoviral mediated gene transfer to secrete GM-CS
Study: NCT00729391

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Woman-Focused Intervention (Women's Health CoOp)
Description: Participants in this group will receive VCT and participate in two group sessions of the woman-focused intervention.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Nutrition (Attention-Control)
Description: Participants in this group will receive VCT and participate in two group sessions of the nutrition intervention.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: VCT Only
Description: Participants in this group will receive VCT only.
Study: NCT01743001

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Macitentan 10 mg
Description: Macitentan 10 mg oral tablet once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Macitentan-matching placebo oral tablet once daily
Study: NCT02470637

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR439065
Description: Pharmaceutical form:dry powder insulin~Route of administration: inhalation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin lispro
Description: Pharmaceutical form:solution for injection~Route of administration: subcutaneous
Study: NCT01515020

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: vancomycin monotherapy
Description: intravenous therapy by vancomycin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: daptomycin monotherapy
Description: intravenous therapy by daptomycin
Study: NCT05258474

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Immediate-release nicotinamide (SAD)
Description: single-ascending dose (SAD)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo controlled-ileocolonic-release nicotinamide (SAD/MAD)
Description: single- and multiple-ascending dose (SAD/MAD)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Immediate-release nicotinamide (SAD)
Description: single-ascending dose (SAD)
Study: NCT00400296

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RG547
Description: Administered iv on days 1 and 8 of a 3 week cycle at escalating doses to successive groups of patients until MTD is reached.
Study: NCT05088239

Intervention type: DRUG
Intervention: prophylactic antibiotics duration
Description: Prophylactic cefazolin 1000 mg was given 30 minutes before surgery, every 4 hours in the peri-operative period, and every 6 hours in the post-operative care. Different discontinued duration of antibiotics was divided to 3 groups in one day, 3 days and until to drain removal.

Intervention type: DRUG
Intervention: prophylactic antibiotics duration
Description: Prophylactic cefazolin 1000 mg was given 30 minutes before surgery, every 4 hours in the peri-operative period, and every 6 hours in the post-operative care. Different discontinued duration of antibiotics was divided to 3 groups in one day, 3 days and until to drain removal.

Intervention type: DRUG
Intervention: prophylactic antibiotics duration
Description: Prophylactic cefazolin 1000 mg was given 30 minutes before surgery, every 4 hours in the peri-operative period, and every 6 hours in the post-operative care. Different discontinued duration of antibiotics was divided to 3 groups in one day, 3 days and until to drain removal.
Study: NCT01692821

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 100% oxygen breathing
Description: 100% oxygen breathing - 30 minutes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 15% oxygen in N2 breathing
Description: 15% oxygen in N2 breathing - 30 minutes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 12% oxygen in N2 breathing
Description: 12% oxygen in N2 breathing - 30 minutes
Study: NCT02251548

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: Oral BTK inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: IV purine analogue chemotherapy agent

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: IV alkylator chemotherapy agent

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: IV anti-CD20 monoclonal antibody
Study: NCT02296138

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: olodaterol
Description: fixed dose combination

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tiotropium
Description: fixed dose combination

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tiotropium
Study: NCT01781091

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: INTELLIVENT ASV FULLY CLOSED-LOOP VENTILATION

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventionals Modes
Study: NCT01322776

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combination of Bortezomib, Fludarabine and Cyclophosphamide
Description: bortezomib 1.3mg/m\^2 i.v. on days 1, 4, 8 and 11 of each 28-day cycle fludarabine 25mg/m\^2 i.v. on days 1\~3 of each 28-day cycle cyclophosphamide i.v. on days 1\~2 of each 28-day cycle
Study: NCT04050020

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Platelet-Rich Plasma (PRP)
Description: All subjects of this group will receive 2 sessions of PRP penile injection with 30 +/- 3 day treatment interval, 10 ml of PRP will be injected at each session.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline injection
Description: All subjects of this group will receive 2 sessions of normal saline penile injection with 30 +/- 3 day treatment interval for all subjects, 10 ml of normal saline will be injected at each session.
Study: NCT02282878

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High/Low Sodium Diet
Description: All patients will receive 2 weeks of the high sodium diet followed by a 1 week washout and then 2 weeks of the low sodium diet

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: High/Low Sodium Diet
Description: All patients will receive 2 weeks of the high sodium diet followed by a 1 week washout and then 2 weeks of the low sodium diet
Study: NCT04531774

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: RECHARGE
Description: RECHARGE is an abbreviated and adapted version of Problem Management Plus (PM+), an evidence-based intervention that helps to cope with stress in times of crisis. Recharge is specifically developed for HCWs as a brief psychological intervention for adults affected by adversity emerging from stress exposure and teaches people three well-documented strategies to manage acute stress. The strategies are: a) managing stress, b) managing worry, c) meaningful activity. It includes psychoeducation, arousal reduction techniques, managing worries and problem-solving skills, behavioural activation, enhancement of meaningful activities, and relapse prevention, which are all based on the principles of cognitive-behavioural therapy.~RECHARGE is delivered online in a 1 to 1 setting between coach and participant. Trained peers (medical doctors, nurses, psychologists) act as coaches.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Self Study
Description: HCWs are referred to a few recommended webpages that outline well-validated, adaptive coping strategies for managing stress.
Study: NCT00703703

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darifenacin
Description: Darifenacin tablets 15 mg once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tolterodine
Description: Tolterodine extended release (ER) 4 mg once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablet once daily
Study: NCT00972699

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer support and mentoring
Description: The intervention will be delivered in 4 non consecutive visits during pregnancy and 4 visits post-partum. The sessions will be delivered to mothers living with HIV on the days of their health care appointments either individually or in groups that can accommodate up to 30 mothers living with HIV. The intervention will focus on enhancing the mother-baby relationship through increasing the health of the mother and baby, maintaining the mother's mental health, and reducing HIV transmission.
Study: NCT03691714

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Two hour infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Two hour infusion for loading dose followed by weekly one hour infusion
Study: NCT04134650

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Linagliptin + metformin
Description: Linagliptin-Metformin 2.5/1700mg daily plus a lifestyle modification program based on nutritional assesment, physical activity prescription and general counseling

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Metformin 1700mg daily plus a lifestyle modification program based on nutritional assesment, physical activity prescription and general counseling
Study: NCT02991599

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 60 µg dose hepatitis B vaccine
Description: three-dose, 60 µg per dose

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 20 µg dose hepatitis B vaccine
Description: three-dose, 20 µg per dose
Study: NCT04528485

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sea swimming
Description: 8 sessions of swimming activities in the sea
Study: NCT01929083

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Progesterone
Description: Subjects will receive oral progesterone 400 mg (two x 200 mg capsules) once daily every evening for 7 days
Study: NCT01312623

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Remote ischemic preconditioning
Description: Remote ischemic preconditioning at the left leg.
Study: NCT01264575

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intrathecal bupivacaine 6 mg with 100 mcg of epinephrine
Description: intrathecal bupivacaine 6 mg with 100 mcg of epinephrine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intrathecal bupivacaine 7 mg with 100 mcg of epinephrine
Description: intrathecal bupivacaine 7 mg with 100 mcg of epinephrine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intrathecal bupivacaine 8 mg with 100 mcg of epinephrine
Description: intrathecal bupivacaine 8 mg with 100 mcg of epinephrine
Study: NCT04792450

Intervention type: DEVICE
Intervention: Thermography
Description: Measure Temperature using Thermal Camera

Intervention type: DEVICE
Intervention: Thermography
Description: Measure Temperature using Thermal Camera